Does the percutaneous approach improve hospital length of stay and discharge disposition compared to surgical cut-down in patients undergoing transfemoral TAVR?
Percutaneous access for transfemoral TAVR optimizes healthcare utilization (shorter LOS, more home discharges) without compromising safety or 12-month mortality compared to surgical cut-down.
For TF TAVR, the PC approach, when compared to the SC approach, is associated with a shorter hospital LOS and higher rate of direct discharge to home with similar risk of vascular complications, late vascular adverse events, and all-cause mortality at 12 months.
Drafts et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: